Indications  
* Parkinson's disease
* prolactinoma/galactorrhoea
* cyclical breast disease
* acromegaly

  
Currently accepted practice in the management of patients with Parkinson's disease is to delay treatment until the onset of disabling symptoms and then to introduce a dopamine receptor agonist. If the patient is elderly, L\-dopa is sometimes used as an initial treatment  
  
Overview  
* e.g. bromocriptine, ropinirole, cabergoline, apomorphine
* ergot\-derived dopamine receptor agonists (bromocriptine, cabergoline, pergolide\*) have been associated with pulmonary, retroperitoneal and cardiac fibrosis. The Committee on Safety of Medicines advice that an ESR, creatinine and chest x\-ray should be obtained prior to treatment and patients should be closely monitored

  
Adverse effects  
* nausea/vomiting
* postural hypotension
* hallucinations
* daytime somnolence

  
\*pergolide was withdrawn from the US market in March 2007 due to concern regarding increased incidence of valvular dysfunction